Piotr Kuszmiersz MD PhD
Piotr has a PhD in Medical Sciences and is an internal medicine specialist, currently undertaking his rheumatology training at the Department of Rheumatology and Immunology, Jagiellonian University Medical College in Kraków, Poland. His research interests focus on patient-reported outcome measures, epidemiology, and the application of AI in medicine. Piotr is a member of the EMEUNET Social Media Sub-Committee.
| Poster 0202 | Saturday, 16.11.24 10:30 Health Services Research – ACR/ARP Poster I Presenting author: M Suarez-Almazor (USA) Title: Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors  This comprehensive SEER-Medicare analysis revealed that TNF inhibitor use in the first three years after early-stage cancer diagnosis did not worsen survival in RA patients with colorectal, lung, or prostate cancer, providing important safety data for this clinical scenario. |
| Poster 1399 | Sunday, 17.11.24 10:30 RA – Treatment Poster II Presenting author: K Franck-Larsson (Sweden) Title: A First-in-Human Clinical Trial Evaluating the Safety and Pharmacokinetics of SOL-116, a Novel Humanized Monoclonal Antibody Targeting Bile Salt-Stimulated Lipase for the Treatment of RA This innovative phase 1 trial demonstrated that SOL-116, a first-in-class anti-BSSL monoclonal antibody, was well-tolerated with predictable pharmacokinetics and effectively eliminated circulating BSSL, representing a promising new therapeutic approach for RA treatment. |
| Oral 1719 | Sunday, 17.11.24 15:00 Abstracts: Health Services Research I Presenting author: B Wallace (USA) Title: Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis: A Nested Case-Control Study This well-designed nested case-control study in a large veteran cohort demonstrated a dose-dependent relationship between cumulative glucocorticoid exposure and major adverse cardiovascular events in RA patients, independent of baseline cardiovascular risk. |
| Oral 1716 | Sunday, 17.11.24 15:00 Abstracts: Epidemiology & Public Health II Presenting author: K Moolooghy (Canada) Title: Comparing the Risk of Sever Infections Associated with Different Classes of Biologic or Targeted Synthetic Agents for Inflammatory Arthritis: A Population-Based Study This large population-based study showed that treatment with rituximab, JAK inhibitors, and anti-IL6 agents was associated with significantly higher risk of severe infections compared to TNF inhibitors in inflammatory arthritis patients, providing crucial real-world safety data to inform treatment decisions. |
| Oral 2672 | Tuesday, 19.11.24 11:00 Abstracts: RA – Treatment II: Refining Use of Established Therapies Presenting author: Q Dumoulin (The Netherlands) Title: Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Methotrexate in ACPA-Negative Arthralgia Patients at Increased Risk for Rheumatoid Arthritis: 4 year Results of the Treat Earlier Trial This groundbreaking randomized controlled trial showed that a one-year course of methotrexate could prevent RA development in ACPA-negative high-risk patients with clinically-suspect arthralgia, reducing RA development from 29.0% to 8.6% over four years. |